Key result
Intravenous infusion of BMS-986231 was safe and well-tolerated for up to 48 hours in healthy volunteers, with headaches being the most common drug-related adverse event.
Why the study?
Nitroxyl has potential therapeutic benefits for acute heart failure, prompting evaluation of the safety, tolerability, and pharmacokinetics of the novel nitroxyl donor BMS-986231 in a first-in-human study.
Is the novel nitroxyl donor BMS-986231 safe and well-tolerated when administered as a 24- or 48-hour intravenous infusion in healthy volunteers?
RCT (n=80)
randomized
Is the novel nitroxyl donor BMS-986231 safe and well-tolerated when administered as a 24- or 48-hour intravenous infusion in healthy volunteers?
The novel nitroxyl donor BMS-986231 is safe and well-tolerated in healthy volunteers, supporting its further evaluation in patients with acute heart failure.
Answers are grounded in this paper and cite their sources.
Supports evaluation in acute HF patients; extends Phase 1 safety data for nitroxyl donors to 48-hour infusions.
Nitroxyl (HNO) is a reactive nitrogen molecule that has potential therapeutic benefits for patients with acute heart failure. The results of the first-in-human study for BMS-986231, a novel HNO donor, are reported. The aim of this sequential cohort study was to evaluate the safety, tolerability, and pharmacokinetic profile of BMS-986231 after 24- and 48-hour intravenous infusions in healthy volunteers. Eighty subjects were randomized and dosed. Seven cohorts (stratum A) received BMS-986231 0.1, 0.33, 1, 3, 5, 10, and 15 μg/kg/min or placebo, infused over 24 hours. An additional cohort (stratum B) received 10 μg/kg/min or placebo, infused over 48 hours. Adverse events (AEs) were reported for 30 days after completion of infusion. Blood/urine samples were collected at regular intervals; other parameters (blood pressure, heart rate/rhythm, cardiac index) were also assessed. Headaches were the most commonly reported drug-related AE (48%) in those who received BMS-986231, although their severity was reduced by hydration. No other significant drug-related AEs were noted. BMS-986231 was associated with dose-dependent and well-tolerated reductions in systolic and diastolic blood pressure versus baseline; cardiac index, as measured noninvasively, was increased. BMS-986231 had no clinically significant effect on heart rate/rhythm or laboratory parameters. Its mean elimination half-life was 0.7-2.5 hours. BMS-986231 was safe and well-tolerated for up to 24 hours (15 μg/kg/min) or 48 hours (10 μg/kg/min), with a favorable hemodynamic profile observed. Ongoing studies continue to evaluate the potential benefit of BMS-986231 in patients with acute heart failure.
No takes yet. Share an insight, caveat, or question.
Cowart et al. (2019) conducted an RCT in Healthy volunteers (n=80). BMS-986231 vs. placebo was evaluated on safety, tolerability, and pharmacokinetic profile. Intravenous infusion of BMS-986231 was safe and well-tolerated for up to 48 hours in healthy volunteers, with headaches being the most common drug-related adverse event.
Synapse has enriched 10 related papers. Consider them for comparative context: